The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-12-15
Просмотров: 77
Описание:
In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, discusses the results of the iMMunoPET study (NCT04814615), a Phase II trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (MM). This tracer demonstrated the ability to detect evidence of disease in patients in whom standard FDG PET/CT was negative, as well as to provide more accurate identification of myeloma sites. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
